MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

233.74
+1.82
+0.78%
Opening 10:03 03/31 EDT
OPEN
228.95
PREV CLOSE
231.92
HIGH
236.20
LOW
228.23
VOLUME
199.53K
TURNOVER
--
52 WEEK HIGH
249.85
52 WEEK LOW
163.68
MARKET CAP
60.60B
P/E (TTM)
51.86
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VRTX stock price target is 267.91 with a high estimate of 300.00 and a low estimate of 224.00.

EPS

VRTX News

More
  • Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View
  • Zacks · 17h ago
  • 4 Reasons Drug Stocks Are a Buy Right Now
  • MotleyFool.com · 23h ago
  • My Top Healthcare Stocks to Buy in the Market Crash
  • MotleyFool.com · 1d ago
  • Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
  • MarketWatch · 1d ago

Industry

Biotechnology & Medical Research
-1.08%
Pharmaceuticals & Medical Research
-0.82%

Hot Stocks

Symbol
Price
%Change

About VRTX

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
More

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.